269 related articles for article (PubMed ID: 34727953)
21. Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells.
Cioce M; Canino C; Pulito C; Muti P; Strano S; Blandino G
Cell Cycle; 2012 Jan; 11(1):132-40. PubMed ID: 22185775
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities.
Nuvoli B; Antoniani B; Libener R; Maconi A; Sacconi A; Carosi M; Galati R
J Exp Clin Cancer Res; 2021 Aug; 40(1):257. PubMed ID: 34404424
[TBL] [Abstract][Full Text] [Related]
23. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Waterhouse DM; Nwokeji ED; Boyd M; Penrod JR; Espirito JL; Robert NJ; Daumont MJ
Future Oncol; 2021 Jul; 17(19):2439-2448. PubMed ID: 33769073
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
25. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
[TBL] [Abstract][Full Text] [Related]
26. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
28. The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.
Oguh-Olayinka L; Agarwal V; Ranatunge D; Campbell A; Laufer S; Cawkwell L; Lind MJ
Pathol Oncol Res; 2020 Apr; 26(2):985-995. PubMed ID: 30941737
[TBL] [Abstract][Full Text] [Related]
29. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
[TBL] [Abstract][Full Text] [Related]
30. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed.
Takeuchi S; Seike M; Noro R; Soeno C; Sugano T; Zou F; Uesaka H; Nishijima N; Matsumoto M; Minegishi Y; Kubota K; Gemma A
Int J Oncol; 2014 Jun; 44(6):1886-94. PubMed ID: 24714722
[TBL] [Abstract][Full Text] [Related]
31. Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation.
Kulkarni NS; Vaidya B; Parvathaneni V; Bhanja D; Gupta V
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878257
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
33. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
[TBL] [Abstract][Full Text] [Related]
34. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
[TBL] [Abstract][Full Text] [Related]
35. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
36. Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.
Dudek AZ; Wang X; Gu L; Duong S; Stinchcombe TE; Kratzke R; Borghaei H; Vokes EE; Kindler HL
Clin Lung Cancer; 2020 Nov; 21(6):553-561.e1. PubMed ID: 32727707
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
38. Isolation of Chemoresistant Cell Subpopulations.
Canino C; Cioce M
Methods Mol Biol; 2016; 1379():139-50. PubMed ID: 26608297
[TBL] [Abstract][Full Text] [Related]
39. Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
Amano Y; Ohta S; Sakura KL; Ito T
Eur J Pharm Sci; 2019 Oct; 138():105008. PubMed ID: 31302213
[TBL] [Abstract][Full Text] [Related]
40. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
